AR069682A1 - Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) - Google Patents

Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)

Info

Publication number
AR069682A1
AR069682A1 ARP080105419A ARP080105419A AR069682A1 AR 069682 A1 AR069682 A1 AR 069682A1 AR P080105419 A ARP080105419 A AR P080105419A AR P080105419 A ARP080105419 A AR P080105419A AR 069682 A1 AR069682 A1 AR 069682A1
Authority
AR
Argentina
Prior art keywords
combination
melanoma
alpha
ctla4
antibodies against
Prior art date
Application number
ARP080105419A
Other languages
English (en)
Spanish (es)
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of AR069682A1 publication Critical patent/AR069682A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP080105419A 2007-12-12 2008-12-12 Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) AR069682A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1310107P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
AR069682A1 true AR069682A1 (es) 2010-02-10

Family

ID=40755783

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105419A AR069682A1 (es) 2007-12-12 2008-12-12 Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)

Country Status (8)

Country Link
US (1) US20100330093A1 (https=)
EP (1) EP2240195A4 (https=)
JP (1) JP2011506436A (https=)
CN (1) CN101896190A (https=)
AR (1) AR069682A1 (https=)
AU (1) AU2008335840A1 (https=)
CA (1) CA2709027A1 (https=)
WO (1) WO2009075813A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
WO2013177102A2 (en) * 2012-05-21 2013-11-28 Felder Mitchell S Treatment of cancer by manipulating the immune system
EP3943101A1 (en) * 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
WO2016133059A1 (ja) * 2015-02-16 2016-08-25 株式会社ファーマフーズ Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
CN109793891A (zh) * 2017-11-17 2019-05-24 韩震 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法
IT201900016310A1 (it) * 2019-09-13 2021-03-13 Luigina Romani Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2604845A1 (de) * 1976-02-07 1977-08-18 Knoll Ag Neue piperazinderivate
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy

Also Published As

Publication number Publication date
US20100330093A1 (en) 2010-12-30
WO2009075813A1 (en) 2009-06-18
EP2240195A1 (en) 2010-10-20
EP2240195A4 (en) 2011-12-21
CA2709027A1 (en) 2009-06-18
JP2011506436A (ja) 2011-03-03
CN101896190A (zh) 2010-11-24
AU2008335840A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
AR069682A1 (es) Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)
AR053651A1 (es) Tratamiento combinado de anticuerpo antictla4 r inhibidor de aromatasa para el cancer de mama
EP1504778A3 (en) Implantable pump for the treatment of obesity
ECSP056076A (es) Sistema de suministro para droga y terapia celular
AU2000277238A1 (en) Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
MY199821A (en) Modified lipidated relaxin b chain peptides and their therapeutic use
AR009757A1 (es) USO DEL COMPUESTO CETRORELIX PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE BPH O CÁNCER DE PRoSTATA EN UN MAMíFERO(
JP2011506436A5 (https=)
AR069767A1 (es) Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa)
TR200002969T2 (tr) Farmasötik bileşim.
TW200637546A (en) Combination therapy
BR0213821A (pt) Conjugados de polìmero/peptìdeo timosina alfa 1
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
BR0213823A (pt) Método de administração de um peptìdeo timosina alfa 1
DE50212918D1 (de) Polypeptid, dessen konjugat doxorubicin enthält, uetzung
AR069769A1 (es) Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas
HK1148938A (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
JP2020524167A5 (https=)
TW200626172A (en) Treatment of HIV infection
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
BR0314253A (pt) Uso de uma combinação de dppe com outros agentes quimioterápicos para o tratamento de câncer de mama
PE20070701A1 (es) Terapia contra el cancer con estrogeno

Legal Events

Date Code Title Description
FA Abandonment or withdrawal